C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics will share new T-cell and NK-cell biomarker findings for cemsidomide plus dexamethasone in RRMM at the 2026 IMS meeting.

Rhea-AI Summary

C4 Therapeutics (CCCC) will present new biomarker data from its Phase 1 trial of cemsidomide plus dexamethasone in relapsed/refractory multiple myeloma at the 23rd International Myeloma Society Annual Meeting.

The poster will detail immunomodulatory effects on T cells and natural killer (NK) cells across once-daily dose levels evaluated in the study, which the company says further support cemsidomide’s potential as a combination partner for immune-based therapies. The meeting will be held in Glasgow, Scotland from September 23–26, 2026.

The poster, titled “T- And NK-Cell Immunomodulatory Reprogramming By Cemsidomide, A Novel And Potent MonoDAC® Degrader, In Relapsed/Refractory Multiple Myeloma: Biomarker Results From CFT7455-1101 Arm B2 Cohort,” is scheduled for September 25, 2026, from 12 pm–1 pm BST / 7 am–8 am ET and will be presented by Riadh Lobbardi, Ph.D., Senior Director of Translational Medicine at C4 Therapeutics.

Argus Sep 3 session 3 alerts

-1.32% close to close 1.7x rel. volume Open Argus

Details

News Market Reaction – CCCC

$469.34M Mkt Cap at Peak Alert

On Sep 3, the day this news came out, CCCC closed 1.32% below the previous close. Our momentum scanner recorded 3 alerts in the available session data. Relative volume reached 1.7x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 3 session.

Key Figures

Trial Phase: Phase 1 trial Meeting Edition: 23rd annual meeting Meeting Dates: September 23–26, 2026 +1 more

Trial Phase

Phase 1 trial

Relapsed/refractory multiple myeloma

Meeting Edition

23rd annual meeting

International Myeloma Society

Meeting Dates

September 23–26, 2026

Glasgow, Scotland

Presentation Date

September 25, 2026

IMS annual meeting poster presentation

Previous Clinical trial Reports

5 past events · Latest: Jun 11

Same Type 5 events

1. Jun 11

   Phase 1 clinical data

   24h Move

   +0.0%

   Updated cemsidomide response and safety data presented at EHA 2026

2. Feb 23

   Phase 2 trial start

   24h Move

   +6.5%

   First patient dosed in the Phase 2 MOMENTUM multiple myeloma trial

3. Oct 01

   Clinical trial collaboration

   24h Move

   -3.1%

   Pfizer collaboration formed for cemsidomide and elranatamab combination

4. Sep 20

   Phase 1 clinical data

   24h Move

   -17.4%

   Cemsidomide multiple myeloma data presented at IMS annual meeting

5. Dec 08

   Phase 1 clinical data

   24h Move

   -5.2%

   Cemsidomide response data presented at ASH annual meeting

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

targeted protein degradation, biomarker, immunomodulatory, natural killer cells, +1 more

5 terms

targeted protein degradation technical

"company dedicated to advancing targeted protein degradation (TPD) science"

Targeted protein degradation is a drug approach that uses small molecules to mark harmful or malfunctioning proteins inside cells so the cell’s own disposal system breaks them down, rather than simply blocking their activity. For investors, it matters because this method can potentially tackle diseases that traditional drugs cannot reach, offering a new class of therapies with broad commercial and patent potential—like switching from silencing a problem to removing it entirely.

biomarker medical

"announced that new biomarker data on the immunomodulatory effects"

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

immunomodulatory medical

"new biomarker data on the immunomodulatory effects of cemsidomide"

Immunomodulatory describes a drug, therapy, or compound that changes how the immune system responds—either boosting, calming, or redirecting its activity. For investors, immunomodulatory products matter because they target many large markets (autoimmune diseases, infections, cancer) and carry distinct safety, trial-design and regulatory risks; think of them as a thermostat for the immune system, where small adjustments can strongly affect effectiveness, side effects and approval chances.

natural killer cells medical

"immune effects on T cells and natural killer (NK) cells"

Natural killer cells are a type of white blood cell that act like the body's rapid-response security guards, identifying and destroying infected or abnormal cells without prior instruction. For investors, they matter because therapies or diagnostics that harness, modify, or measure these cells can drive drug development, clinical trial results, and company valuation in areas like cancer and infectious disease—think of them as a promising tool in the toolbox of immune-based treatments.

relapsed/refractory multiple myeloma medical

"trial for relapsed/refractory multiple myeloma (RRMM)"

A form of multiple myeloma (a cancer of plasma cells) that has either returned after an initial response to therapy (relapsed) or stopped responding to one or more treatments (refractory). Think of it like weeds that come back after being pulled or that no longer die from a usual herbicide; these cases are harder to control and often need new or stronger therapies. For investors, relapsed/refractory status signals a larger, urgent market for next-generation drugs, impacts clinical trial design and success rates, and can drive regulatory approval and long-term revenue potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that new biomarker data on the immunomodulatory effects of cemsidomide in combination with dexamethasone from its Phase 1 trial for relapsed/refractory multiple myeloma (RRMM) will be presented in a poster at the 23^rd IMS Annual Meeting. The data characterize the immune effects on T cells and natural killer (NK) cells across the once-daily dose levels evaluated in the Phase 1 trial, further supporting cemsidomide’s potential as a combination partner for immune-based therapies. The meeting will take place in Glasgow, Scotland from September 23 – 26, 2026.

Poster Presentation Details:
Title: T- And NK-Cell Immunomodulatory Reprogramming By Cemsidomide, A Novel And Potent MonoDAC^® Degrader, In Relapsed/Refractory Multiple Myeloma: Biomarker Results From CFT7455-1101 Arm B2 Cohort.
Presentation Date and Time: September 25, 2026, from 12 pm – 1 pm BST / 7 am – 8 am ET
Presenter: Riadh Lobbardi, Ph.D., Senior Director of Translational Medicine, C4 Therapeutics

About Cemsidomide
Cemsidomide is an investigational, next-generation orally bioavailable MonoDAC^® degrader (molecular glue) of IKZF1/3, transcription factors foundational to multiple myeloma biology. Data from the fully enrolled Phase 1 trial show cemsidomide’s differentiated safety and tolerability profile and potentially class-leading anti-myeloma activity that supports the potential for durable outcomes.

About Multiple Myeloma
Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow. It is the second most common blood cancer, with approximately 36,000 people in the United States diagnosed each year. Multiple myeloma is characterized by cycles of remission and relapse, which leads to patients needing multiple lines of therapy to manage the persistent disease. More than 175,000 patients in the United States are estimated to be living with or in remission from myeloma. However, despite treatment advances, approximately 40% of patients do not survive beyond five years.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors: 
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com

Media: 
Loraine Spreen 
Senior Director, Corporate Communications & Patient Advocacy 
LSpreen@c4therapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is C4 Therapeutics (CCCC) presenting at the 23rd IMS Annual Meeting?

C4 Therapeutics (CCCC) will present new biomarker data on the immunomodulatory effects of cemsidomide plus dexamethasone from its Phase 1 relapsed/refractory multiple myeloma trial, focusing on T-cell and natural killer (NK) cell immune effects across once-daily dose levels.

When and where will C4 Therapeutics’ cemsidomide Phase 1 biomarker data be presented?

The biomarker data will be presented as a poster at the 23rd International Myeloma Society Annual Meeting in Glasgow, Scotland. The specific poster session is scheduled for September 25, 2026, from 12 pm–1 pm BST / 7 am–8 am ET.

Who will present the cemsidomide biomarker poster for C4 Therapeutics (CCCC)?

The cemsidomide biomarker poster will be presented by Riadh Lobbardi, Ph.D., Senior Director of Translational Medicine at C4 Therapeutics, during the September 25, 2026 poster session at the 23rd International Myeloma Society Annual Meeting.

What aspects of the immune system are analyzed in C4 Therapeutics’ cemsidomide biomarker data?

The biomarker data characterize the immunomodulatory effects of cemsidomide plus dexamethasone on T cells and natural killer (NK) cells across once-daily dose levels in the Phase 1 relapsed/refractory multiple myeloma trial, which the company says supports its potential as a combination partner for immune-based therapies.